Brief: Aptinyx Completes Enrollment In Phase 2B Study Of NYX-2925 In Painful Diabetic Peripheral Neuropathy
27/10/2021 13:31
Oct 27 (Reuters) - Aptinyx Inc APTX.O :
* APTINYX COMPLETES ENROLLMENT IN PHASE 2B STUDY OF NYX-2925
IN
PAINFUL DIABETIC PERIPHERAL NEUROPATHY
* APTINYX INC - RESULTS FROM PHASE 2B STUDY ARE EXPECTED IN
EARLY
TO MID 2Q 2022
Source text for Eikon: ID:nBw6kRJJRa
Further company coverage: APTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptinyx
See all newsBrief: Aptinyx Gets Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Aptinyx Inc reports On May 4, Board Deemed It In Best Interests Of Co And Its Stockholders That Co Be Dissolved
Aptinyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aptinyx Inc Reports Quarterly Loss Per Share Of $0.18
Aptinyx Inc expected to post a loss of 19 cents a share - Earnings Preview